How does the management of COPD exacerbations differ in patients with type 2 diabetes compared to those without diabetes?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18530016
Cited by: 0

Abstract

SGLT-2 inhibitors and GLP-1 receptor agonists show promise in reducing the frequency of COPD exacerbations in patients with type 2 diabetes, while metformin's direct benefits on exacerbation outcomes are less clear.

Fields of Study & Subjects

Chronic Obstructive Pulmonary Disease (COPD) Research Diabetes Treatment and Management Asthma and respiratory diseases

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
9 February 2026